drugset
drugset / Trial / NCT02933528

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

NCT02933528 ↗

Phase 2 Completed 24 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .

Timeline

Start
2016-07-11
Primary completion
2017-08-11
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject DSXS Topical product Unknown — Topical

Indications

psoriasis